Skip to main content
. 2020 May 1;2020(5):CD008649. doi: 10.1002/14651858.CD008649.pub4

Comparison 5. Mannitol plus dornase alfa versus dornase alfa ‐ cross‐over study of individuals with cystic fibrosis.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
5.1 FEV1 (% change from baseline) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1.1 Up to 3 months 1 40 Mean Difference (IV, Fixed, 95% CI) ‐4.30 [‐14.10, 5.50]
5.2 FVC (% change from baseline) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.2.1 Up to 3 months 1 40 Mean Difference (IV, Fixed, 95% CI) ‐0.07 [‐0.30, 0.16]
5.3 FEF25-75 (% change from baseline) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.3.1 Up to 3 months 1 20 Mean Difference (IV, Fixed, 95% CI) 0.03 [‐0.18, 0.24]